Structure Therapeutics Inc. - American Depositary Shares (GPCR)
53.48
+3.31 (6.60%)
NASDAQ · Last Trade: Apr 4th, 5:14 AM EDT
Detailed Quote
Previous Close
50.17
Open
48.29
Bid
51.80
Ask
54.75
Day's Range
48.00 - 55.75
52 Week Range
13.22 - 94.90
Volume
1,708,677
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,078,992
Chart
About Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Structure Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of innovative therapies targeting G protein-coupled receptors (GPCRs), which are essential in mediating various physiological processes and diseases. By leveraging advanced structural biology and computational techniques, the company aims to design small molecule treatments for a range of conditions, including metabolic disorders and neurodegenerative diseases. Through its research efforts, Structure Therapeutics strives to create effective and targeted therapeutics that can improve patient outcomes and contribute to advancements in personalized medicine. Read More
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for GLP-1 receptor agonists and multi-pathway incretins, once estimated to be a two-horse race, is now the frontline of a
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require strict fasting or water intake restrictions. The approval, which came months ahead of initial analyst expectations, marks a pivotal
The financial landscape of 2026 has been defined by a singular, tectonic shift that few predicted would be this absolute: the definitive end of the mega-cap tech era and the roaring resurgence of the "real economy." As of late March 2026, the Russell 2000 index is not just outperforming the
The financial landscape has undergone a tectonic shift in the opening months of 2026, as the long-dormant Russell 2000 index has surged to record highs, marking what many analysts believe is the definitive end of mega-cap dominance. After trailing the S&P 500 (NYSEARCA: SPY) for over a decade, small-cap
As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is fundamentally decoupling from the mega-cap tech giants that dominated the previous era. In the first
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the undisputed "darling" of the global equity markets, propelled by the unprecedented success of its GLP-1 (glucagon-like peptide-1) agonists, Ozempic and Wegovy. However, the early months [...]
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion market capitalization. This monumental achievement, finalized in early February 2026, marks a paradigm shift in how investors value
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83 billion. The announcement, made during the company’s early February earnings call, marks a historic turning point in the pharmaceutical
A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but that hasn't stopped the pharmaceutical stock from surging.
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent expirations and the first tangible impacts of the Inflation Reduction Act (IRA), Big Pharma is entering the year with record-high cash
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and
As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in mega-cap technology stocks, the final quarter of 2025 has seen a decisive shift in investor sentiment—
